Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESULT: Resveratrol and Sirolimus in LAM
NCT03253913Phase 2Completed
- Sponsor
- University of Cincinnati
- Start
- Mar 2018
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of resveratrol in lymphangioleiomyomatosis (LAM), sponsored by University of Cincinnati. Primary endpoint: Serum Vascular Endothelial Growth Factor-D Levels at 24 weeks. Started Mar 2018; status: completed.
02
Drugs
resveratrol
03
Conditions
lymphangioleiomyomatosis (LAM)
Beyond the preview
Go deeper on NCT03253913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03253913.